Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on pioneering transformative cell and exosome-based therapies to treat and prevent a diverse range of diseases and disorders. Their lead therapeutic, CAP-1002, is an allogeneic cell therapy derived from heart tissue. This candidate has successfully completed its Phase III clinical trial for patients afflicted with late-stage Duchenne muscular dystrophy (DMD). CAP-1002 is simultaneously progressing through Phase II clinical testing to address cytokine storm associated with SARS-CoV-2. Beyond CAP-1002, the company is advancing CAP-2003 through preclinical development, aiming to treat trauma-related injuries and medical conditions. Furthermore, Capricor is developing two vaccine candidates with the potential to prevent COVID-19. Capricor collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, supporting its use in DMD and other indications. The company was established in 2005 and is headquartered in San Diego, California.
